CONCLUSION
Everolimus is a subtrate of CYP3A4 and P-glycoprotein whose blood concentrations can be seriously affected by drug interaction at that level, eventually implying underexposure to everolimus. Therefore, TDM should be used whenever potential metabolism drug-drug interactions are detected in cancer patients to monitor drug levels and to contribute to achieve the optimal Css ultimately associated with better response and a lower toxicity profile.